Ayala Pharmaceuticals, Inc. - Common Stock (NQ:AYLA)

N/A UNCHANGED

Last Price Updated: 3:56 PM EST, Jan 18, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ayala Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 10, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 03, 2023

On Tuesday, 31 stocks hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 27, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 29, 2022

Via Benzinga

Recap: Ayala Pharmaceuticals Q3 Earnings ↗

November 04, 2022

Ayala Pharmaceuticals (NASDAQ:AYLA) reported its Q3 earnings results on Friday, November 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

November 17, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

November 16, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 04, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

November 11, 2022

On Friday, 63 stocks hit new 52-week lows.

Via Benzinga

AutoZone To Rise Over 9%? Plus Roth Capital Slashes PT On This Stock By 96% ↗

October 20, 2022

Raymond James raised the price target on AutoZone, Inc. (NYSE: AZO) from $2,350 to $2,500. AutoZone shares fell 0.7% to close at $2,289.80 on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 19, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ ↗

October 19, 2022

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement.

Via Benzinga

AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders

October 19, 2022

From Halper Sadeh LLC

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗

October 20, 2022

Upgrades

Via Benzinga

Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

October 19, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 17, 2022

Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million.

Via Benzinga

Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday ↗

October 20, 2022

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of...

Via Benzinga

Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session ↗

October 19, 2022

Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share.

Via Benzinga

Short Volatility Alert: Ayala Pharmaceuticals, Inc. ↗

October 03, 2022

On Friday, shares of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) experienced volatile short activity. After the activity, the stock price went up +7.00% to $1.00. The overall sentiment for AYLA has been...

Via Benzinga

Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors

September 29, 2022

From Ayala Pharmaceuticals

Via GlobeNewswire

Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗

September 28, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 20, 2022

Via Benzinga

Analyzing Ayala Pharmaceuticals's Short Interest ↗

September 13, 2022

Ayala Pharmaceuticals's (NASDAQ:AYLA) short percent of float has risen 1512.0% since its last report. The company recently reported that it has 246 thousand shares sold short,...

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session ↗

September 12, 2022

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

September 09, 2022

It's time for another deep dive into the biggest pre-market stock movers for Friday and the news that has these shares moving this morning.

Via InvestorPlace

Why Zumiez Is Trading Lower By 14%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2022

Gainers Infobird Co., Ltd (NASDAQ: IFBD) rose 70.8% to $3.16 in pre-market trading after 1:5 reverse stock split takes effect.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 08, 2022

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.